2022 World Conference on Lung Cancer (ePosters)-EP08.02-148. Extended Follow-up of Efficacy and Safety of Larotrectinib in Patients With TRK Fusion Lung Cancer

EP08.02-148. Extended Follow-up of Efficacy and Safety of Larotrectinib in Patients With TRK Fusion Lung Cancer

Pdf Summary

The study evaluated the efficacy and safety of larotrectinib in patients with TRK fusion lung cancer. The ORR for patients in the Group 2 dataset was 83%, with a duration of response, progression-free survival, and overall survival rates of 72%, 67%, and 72% at 24 months, respectively. The median time to response was 1.8 months, and the duration of treatment ranged from 2.1 to 52.7 months. In patients with known baseline CNS metastases, the ORR was 80% with median DoR, PFS, and OS of 9.5, 9.9, and 19.4 months, respectively. The study also reported the baseline characteristics of patients in the Group 1 and Group 2 datasets, including age, sex, fusion partners, prior therapies, and best response to prior therapy.<br /><br />The efficacy of larotrectinib remained consistent in the Group 1 dataset with an additional year of follow-up, with an ORR of 87% for the 15 IRC-evaluable patients. The median DoR was not reached at a median follow-up of 24.0 months, and the median PFS and OS were 33.0 and 40.7 months, respectively. No new safety signals were identified in the Group 1 dataset with extended follow-up. For the Group 2 dataset, treatment-related adverse events were predominantly Grade 1/2, and there were no treatment discontinuations due to adverse events.<br /><br />The study concludes that larotrectinib demonstrated rapid and durable responses, extended survival, and a favorable long-term safety profile in patients with advanced TRK fusion lung cancer. The results support testing for NTRK gene fusions in patients with lung cancer.

Asset Subtitle

Victor Moreno

Meta Tag

Speaker Victor Moreno

Topic Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments

Keywords

larotrectinib

TRK fusion lung cancer

efficacy

safety

ORR

duration of response

progression-free survival

overall survival

CNS metastases

baseline characteristics